Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.
about
A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction.Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial dataAdverse effects of long-term proton pump inhibitor therapy.Mechanism of acid hypersecretion post curative gastrinoma resectionSystems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.How May Proton Pump Inhibitors Impair Cardiovascular Health?A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in CatsAcid inhibition and the acid rebound effect.Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.The regulation of gastric acid secretion - clinical perspectives.Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors.Gastrointestinal hormone research - with a Scandinavian annotation.Algorithm of medication review in frail older people: Focus on minimizing the use of high-risk medications.Rebound acid hypersecretion.Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.Proton-pump inhibitors among adults: a nationwide drug-utilization study.
P2860
Q30276528-7B937A13-ADF9-441B-9AAE-CCCE12BFCB13Q33993694-D1D7DE37-8A27-4BB3-AF0D-7599BB93F92BQ34167899-F58AF9DE-D012-4022-8D4D-7F11026C1C26Q34345074-6B720C3B-5255-425A-BDB6-123AFD0CAE9AQ34519283-C55C1F66-A725-4CD3-A3FE-24BC93DBAA6DQ36892867-2D0FE6F3-C14B-4CB3-BE66-80CFE3127915Q37020253-D915BA31-C97F-4E96-81D5-DFBBD539C78AQ37957706-FBE16BC6-875C-446D-8E5F-EAC9CCBC277CQ38073333-6B621516-E016-4D56-AF9F-93E969978AC2Q38166450-36C5D1B3-3494-4521-AFDD-04E8C45DB71FQ38266846-1E6020A6-0BD6-48BB-B890-25A5BC2ACF2FQ38382950-1F24507C-58DE-45BD-8D5F-19845FD685FAQ38580499-565A31B5-3CF9-41A8-B537-B1BAEBCFDF55Q43123706-7D8E86DE-8D77-43E0-8EFE-0FF999FF4ACDQ51385134-05293472-6969-4ED4-981F-C38263B6972CQ55289788-604BEEEB-05FE-487F-8A4C-082E085DD6C8
P2860
Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@en
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@nl
type
label
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@en
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@nl
prefLabel
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@en
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@nl
P2093
P2860
P1476
Rebound acid hypersecretion fr ...... ogical and clinical viewpoint.
@en
P2093
Arne K Sandvik
Gunnar Qvigstad
Helge L Waldum
Per M Kleveland
Reidar Fossmark
P2860
P304
P356
10.3109/00365520903477348
P577
2010-04-01T00:00:00Z